AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26417957 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 168
Study 24886398 — intervention group
Group type: EXPERIMENTAL
Intervention: FACETS plus current local practice (FACETS)
Number of subjects: 164
Study 24886398 — intervention group
Group type: COMPARATOR
Intervention: Current local practice alone (CLP)
Number of subjects: 164
Study 21254871 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg of ethinyl estradiol (EE)/3 mg of drospirenone (DRSP) plus 100 mg of cyproterone acetate (CPA)
Number of subjects: 134
Study 21254871 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg of EE/3 mg of DRSP plus 100 mg of spironolactone
Number of subjects: 134
Study 21254871 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 μg of EE/2 mg of CPA plus 100 mg of CPA
Number of subjects: 134
Study 19728070 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic drinks (target blood alcohol content of .06, .08, or .10%)
Number of subjects: 64
Study 19728070 — intervention group
Group type: COMPARATOR
Intervention: Non-alcoholic drinks
Number of subjects: 64
Study 19728070 — intervention group
Group type: EXPERIMENTAL
Intervention: CSA women
Number of subjects: 64
Study 19728070 — intervention group
Group type: COMPARATOR
Intervention: NSA and ASA women
Number of subjects: 64
Study 18727456 — intervention group
Group type: EXPERIMENTAL
Intervention: [methyl‐13C]‐methionine
Number of subjects: 15
Study 18727456 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐methionine‐1‐13COOH
Number of subjects: 15
Study 16166189 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 40
Study 16166189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12087783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot program for smoking cessation
Number of subjects: 20
Study 12087783 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 20
Study 10944138 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusions (DLI)
Number of subjects: 27
Study 10944138 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinduction therapy before DLI
Number of subjects: 27
Study 10944138 — intervention group
Group type: EXPERIMENTAL
Intervention: DLI
Number of subjects: 27
Study 8839865 — intervention group
Group type: EXPERIMENTAL
Intervention: K-ras mutations
Number of subjects: 160
Study 8839865 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP treatment
Number of subjects: 160
Study 8839865 — intervention group
Group type: COMPARATOR
Intervention: VBMCP + interferon-alpha
Number of subjects: 160
Study 8839865 — intervention group
Group type: EXPERIMENTAL
Intervention: VBMCP + alternating high doses of cyclophosphamide + prednisone
Number of subjects: 160
Study 1592959 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 66
Study 1592959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 1592959 — intervention group
Group type: COMPARATOR
Intervention: No-pill condition
Number of subjects: 66
Study 6375611 — intervention group
Group type: EXPERIMENTAL
Intervention: IVT team maintained IV catheters
Number of subjects: 863
Study 6375611 — intervention group
Group type: COMPARATOR
Intervention: Ward staff maintained IV catheters
Number of subjects: 863
Study 31672709 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard PEEP (6-8 cm H2O)
Number of subjects: 208
Study 31672709 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP (≤2 cm H2O)
Number of subjects: 208
Study 30621562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment plus ZQMT
Number of subjects: 144
Study 30621562 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal ranibizumab treatment alone
Number of subjects: 144
Study 26979174 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 1710
Study 26979174 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1710
Study 25248996 — intervention group
Group type: EXPERIMENTAL
Intervention: SASA! community mobilization intervention
Number of subjects: 2583
Study 22646056 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral-to-tilt position
Number of subjects: 51
Study 22646056 — intervention group
Group type: COMPARATOR
Intervention: Supine-to-tilt position
Number of subjects: 51
Study 20353026 — intervention group
Group type: EXPERIMENTAL
Intervention: Er'zhi Tiangui Granule (ETG)
Number of subjects: 57
Study 20353026 — intervention group
Group type: COMPARATOR
Intervention: Liuwei Dihuang Granule (LDG)
Number of subjects: 57
Study 16757485 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa treatment
Number of subjects: 224
Study 16757485 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 224
Study 16757485 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 224
Study 16757485 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch FIQ
Number of subjects: 224
Study 15749042 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg daily for 3 days)
Number of subjects: 509
Study 15749042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 15749042 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 509
Study 11423507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 8 mg daily
Number of subjects: 319
Study 11423507 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg daily
Number of subjects: 319
Study 11423507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 319
Study 9404750 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow-based action plan
Number of subjects: 150
Study 9404750 — intervention group
Group type: COMPARATOR
Intervention: Symptom-based action plan
Number of subjects: 150
Study 9404750 — intervention group
Group type: COMPARATOR
Intervention: No action plan
Number of subjects: 150
Study 8356999 — intervention group
Group type: EXPERIMENTAL
Intervention: nabumetone
Number of subjects: 4411
Study 8356999 — intervention group
Group type: COMPARATOR
Intervention: comparator NSAIDs
Number of subjects: 4411
Study 8356999 — intervention group
Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 4411
Study 8356999 — intervention group
Group type: COMPARATOR
Intervention: naproxen
Number of subjects: 4411
Study 8356999 — intervention group
Group type: COMPARATOR
Intervention: piroxicam
Number of subjects: 4411
Study 8356999 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen
Number of subjects: 4411
Study 3314750 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded-sequential filling
Number of subjects: 136
Study 3314750 — intervention group
Group type: COMPARATOR
Intervention: Uniform compression - multiple compartments
Number of subjects: 136
Study 3314750 — intervention group
Group type: COMPARATOR
Intervention: Uniform pressure - single bladder
Number of subjects: 136
Study 2694799 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of Madopar HBS
Number of subjects: 14
Study 2694799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 4593130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 20
Study 4593130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine with theophylline
Number of subjects: 20
Study 4593130 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (as an addition to ephedrine)
Number of subjects: 20
Study 31428804 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 31428804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28089709 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary interventions based on WHO healthy eating guidelines (increase fruits, vegetables, whole grains, dietary fibre; decrease fats, sugars, and salt)
Number of subjects: 20
Study 28089709 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary metabolite models
Number of subjects: 20
Study 25432773 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (50 mg once weekly)
Number of subjects: 16713
Study 25432773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16713
Study 23188489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 7376
Study 23188489 — intervention group
Group type: COMPARATOR
Intervention: 2009 A(H1N1) pandemic
Number of subjects: 7376
Study 21727175 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized cardiopulmonary bypass (MCPB)
Number of subjects: 40
Study 21727175 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (CCPB)
Number of subjects: 40
Study 19553414 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care (n = 115)
Number of subjects: 227
Study 19553414 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 112)
Number of subjects: 227
Study 16690557 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum tablets
Number of subjects: 0
Study 16690557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14961882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening group
Number of subjects: 15151
Study 14961882 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15151
Study 11401812 — intervention group
Group type: COMPARATOR
Intervention: Signature group (control)
Number of subjects: 110
Study 11401812 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-signature group (experimental)
Number of subjects: 110
Study 11401812 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (signature and non-signature)
Number of subjects: 110
Study 9260215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with house dust mite extract (D.pt.)
Number of subjects: 30
Study 9260215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8280542 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-gauge spinal catheters
Number of subjects: 68
Study 3566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate 0.3%
Number of subjects: 34
Study 3566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 0.5%
Number of subjects: 34
Study 3566442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 29412458 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine (TRV130) administered in doses ranging from 0.5 to 4 mg every 3-4 hours during the phase 2 study.
Number of subjects: 410
Study 29412458 — intervention group
Group type: EXPERIMENTAL
Intervention: Oliceridine (TRV130) administered in single doses ranging from 0.15 to 7 mg and multiple doses ranging from 0.4 to 4.5 mg every 4-6 hours during the phase 1 study.
Number of subjects: 410
Study 29412458 — intervention group
Group type: COMPARATOR
Intervention: Placebo group during the phase 2 study.
Number of subjects: 410
Study 27074824 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone (2.5, 5, 7.5, 10 or 15 mg, up-titrated to 5, 10, 15, 20, or 20 mg, respectively, on day 30)
Number of subjects: 72
Study 27074824 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone (25 mg every other day, increased to 25 mg o.d. on day 30, and 50 mg on day 60)
Number of subjects: 72
Study 27074824 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 72
Study 24113927 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol smokers
Number of subjects: 166
Study 24113927 — intervention group
Group type: COMPARATOR
Intervention: Nonmenthol smokers
Number of subjects: 166
Study 24113927 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol smokers who quit
Number of subjects: 166
Study 22954020 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-back test
Number of subjects: 18
Study 22954020 — intervention group
Group type: COMPARATOR
Intervention: 0-back test
Number of subjects: 18
Study 20826243 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose followed by 75 mg/d) + Aspirin (75 mg/d for first 21 days)
Number of subjects: 5100
Study 20826243 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (75 mg/d) alone
Number of subjects: 5100
Study 19030110 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative Risk Reduction (RRR)
Number of subjects: 770
Study 19030110 — intervention group
Group type: COMPARATOR
Intervention: Absolute Risk Reduction, Number Needed to Treat, Event Rates, Tablets Needed to Take, Natural Frequencies
Number of subjects: 770
Study 16649375 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's milk
Number of subjects: 312
Study 16649375 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl alcohol 96%
Number of subjects: 312
Study 16649375 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine
Number of subjects: 312
Study 16649375 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 312
Study 12815479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 23
Study 12815479 — intervention group
Group type: COMPARATOR
Intervention: Control (high-dose therapy only)
Number of subjects: 23
Study 12815479 — intervention group
Group type: COMPARATOR
Intervention: Control (contaminated samples)
Number of subjects: 23
Study 11101185 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 88 microg BID
Number of subjects: 437
Study 11101185 — intervention group
Group type: COMPARATOR
Intervention: Zafirlukast 20 mg BID
Number of subjects: 437
Study 9159696 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interventions
Number of subjects: 12
Study 9159696 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 12
Study 8513521 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 30
Study 8513521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 30
Study 8513521 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 30
Study 3317128 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri-Strip tape suture
Number of subjects: 264
Study 3317128 — intervention group
Group type: COMPARATOR
Intervention: Conventional continuous 3‐o or 4‐o Dermalon suture
Number of subjects: 264
Study 31135929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic and rad-board lead shields during coronary angiography (CA) procedures
Number of subjects: 418
Study 31135929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic and rad-board lead shields during angioplasty (PCI) procedures
Number of subjects: 418
Study 31135929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic and rad-board lead shields
Number of subjects: 418
Study 29338824 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training (IE)
Number of subjects: 22
Study 29338824 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training with whey protein isolate supplement (IE + WPI)
Number of subjects: 22
Study 25965871 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-evaluative context (SET) stressor
Number of subjects: 144
Study 25965871 — intervention group
Group type: COMPARATOR
Intervention: Non-evaluative context (non-SET) stressor
Number of subjects: 144
Study 25965871 — intervention group
Group type: EXPERIMENTAL
Intervention: Trait rumination
Number of subjects: 144
Study 25965871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in rumination
Number of subjects: 144
Study 23601460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin dexamethasone eye ointment
Number of subjects: 148
Study 23601460 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin eye ointment (Control)
Number of subjects: 148
Study 21369670 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 243
Study 21369670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 19101099 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation Enhancement Therapy (MET)
Number of subjects: 200
Study 19101099 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 200
Study 17060388 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 500
Study 17060388 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 500
Study 12735660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dose regimen of formoterol (9 + 9 + 18 microg, total 36 microg)
Number of subjects: 16
Study 12735660 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high dose of formoterol (36 microg)
Number of subjects: 16
Study 12735660 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens (cumulative and single high dose)
Number of subjects: 16
Study 10620003 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (EPA 3.2 g, DHA 2.4 g)
Number of subjects: 18
Study 10620003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8841150 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline (4 mg/day, n = 6)
Number of subjects: 15
Study 8841150 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline (16 mg/day, n = 3)
Number of subjects: 15
Study 8841150 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline (optimal dose for memory enhancement)
Number of subjects: 15
Study 8841150 — intervention group
Group type: EXPERIMENTAL
Intervention: Arecoline (0.5 to 40 mg/day during multiple-dose infusions)
Number of subjects: 15
Study 8841150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 15
Study 1627957 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 32
Study 1627957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 6435644 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate spray (2 sprays, 2.5 mg)
Number of subjects: 9
Study 6435644 — intervention group
Group type: COMPARATOR
Intervention: Sublingual glyceryl trinitrate (0.3 mg)
Number of subjects: 9
Study 6435644 — intervention group
Group type: COMPARATOR
Intervention: Ordinary isosorbide dinitrate tablet (5 mg)
Number of subjects: 9
Study 30895698 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow diameter implants (NDIs) (< 3.3 mm)
Number of subjects: 86
Study 30895698 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular diameter implants (RDIs) (4.1 mm)
Number of subjects: 86
Study 30895698 — intervention group
Group type: COMPARATOR
Intervention: Narrow diameter implants (NDIs) and Regular diameter implants (RDIs)
Number of subjects: 86
Study 30189773 — intervention group
Group type: EXPERIMENTAL
Intervention: ShcA expression measured by immunofluorescence in kidney tissues from LN patients
Number of subjects: 92
Study 30189773 — intervention group
Group type: COMPARATOR
Intervention: ShcA expression in primary and other secondary MN
Number of subjects: 92
Study 26630947 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Incision Sling (SIS)
Number of subjects: 93
Study 26630947 — intervention group
Group type: COMPARATOR
Intervention: Transobturator Sling (TOT)
Number of subjects: 93
Study 24190907 — intervention group
Group type: EXPERIMENTAL
Intervention: Real interpersonal touch (brief touch on the shoulder by a female experimenter)
Number of subjects: 0
Study 24190907 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated interpersonal touch (holding a teddy bear)
Number of subjects: 0
Study 24190907 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated interpersonal touch (higher value estimates of a teddy bear)
Number of subjects: 0
Study 24190907 — intervention group
Group type: COMPARATOR
Intervention: Control (cardboard box)
Number of subjects: 0
Study 22547887 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 50
Study 22547887 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 50
Study 20580303 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 41
Study 20580303 — intervention group
Group type: COMPARATOR
Intervention: Sham needle control
Number of subjects: 41
Study 17123696 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients
Number of subjects: 90
Study 17123696 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients without insulin resistance
Number of subjects: 90
Study 17123696 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS patients with insulin resistance
Number of subjects: 90
Study 17123696 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 16036044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 16036044 — intervention group
Group type: EXPERIMENTAL
Intervention: Conivaptan
Number of subjects: 0
Study 16036044 — intervention group
Group type: COMPARATOR
Intervention: Loop diuretics
Number of subjects: 0
Study 11987088 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic varicocelectomy (LV)
Number of subjects: 654
Study 11987088 — intervention group
Group type: COMPARATOR
Intervention: Open varicocelectomy (OV)
Number of subjects: 654
Study 9607623 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain group
Number of subjects: 115
Study 9607623 — intervention group
Group type: COMPARATOR
Intervention: No-drain group
Number of subjects: 115
Study 9144613 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol based bisacodyl suppository (PEGBS)
Number of subjects: 19
Study 9144613 — intervention group
Group type: COMPARATOR
Intervention: Conventional bisacodyl suppository based in hydrogenated vegetable oil (HVOBS)
Number of subjects: 19
Study 2250039 — intervention group
Group type: EXPERIMENTAL
Intervention: Home interviews
Number of subjects: 0
Study 2250039 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal questionnaire
Number of subjects: 0
Study 2250039 — intervention group
Group type: COMPARATOR
Intervention: Medical records
Number of subjects: 0
Study 7011349 — intervention group
Group type: COMPARATOR
Intervention: salbutamol (0.15 micrograms kg‐1 min‐1 for 30 min)
Number of subjects: 4
Study 7011349 — intervention group
Group type: COMPARATOR
Intervention: aminophylline (0.2 mg kg‐1 min‐1 for 30 min)
Number of subjects: 4
Study 7011349 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol, salbutamol (SS)
Number of subjects: 4